Quick Take: AACR 2026 Abstract Titles Out; Hansoh and Zai Lab with Key Presentations on ADCs
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
With AACR 2026 abstract titles now released and full content embargoed until April 17, 2026, Bernstein highlights critical clinical and preclinical updates from covered companies. Hansoh's Phase 1 ARTEMIS-101 trial evaluating HS-20093, a B7H3 ADC, combined with a PD-L1 antibody for second-line or later NSCLC stands out as the most impactful abstract. Previously presented data from December 2025 ESMO Asia demonstrated a 33% overall response rate (ORR) and a median progression-free survival (mPFS) of 7 months in third-line NSCLC. Because B7H3 ADCs are typically associated with small cell lung cancer, any application in NSCLC represents meaningful upside potential.
Zai Lab features two notable abstracts regarding ZL-1310, a DLL3 ADC, focusing respectively on intracranial activity in ES-SCLC patients with baseline brain metastases and efficacy across neuroendocrine cancers and other solid tumors. Hengrui has disclosed HRS-6209, a highly selective CDK4 inhibitor in Phase 1 trials for advanced solid tumors, alongside multiple preclinical assets including trispecific antibodies. BeOne Medicines introduces a SMAC mimetic, BGB-24714, into its solid tumor pipeline, while Akeso reports Phase 2 results for cadonilimab in first-line PDAC. Innovent is presenting a CD16A nanobody platform designed to address Fc receptor polymorphism, potentially offering a modular engine for consistent NK cell engager therapies.